Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High-Dose Lipitor Is As Safe As Lower Doses, Pfizer Analysis Finds

Executive Summary

Treatment-related adverse events for Lipitor 80 mg were similar to those for atorvastatin 10 mg, according to a Pfizer analysis of pooled studies of the cholesterol-lowering drug reported in the January issue of the American Journal of Cardiology

You may also be interested in...



Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed

Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin

Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed

Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin

High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests

Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel